Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Treace Medical Concepts (NAS:TMCI) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Treace Medical Concepts's Enterprise Value for the quarter that ended in Jun. 2026 was $285.7 Mil.
Treace Medical Concepts's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Treace Medical Concepts EV-to-EBIT Related Terms
Treace Medical Concepts EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Treace Medical Concepts's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Treace Medical Concepts EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Treace Medical Concepts's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Treace Medical Concepts's EV-to-EBIT falls into.
Treace Medical Concepts's current Enterprise Value is $338.3 Mil.
Treace Medical Concepts's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Treace Medical Concepts (TMCI) has a EV-to-EBIT of -6.30 as of Aug. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Treace Medical Concepts and its competitors. According to the industry distribution chart, Treace Medical Concepts ranks #999999 out of 473 companies in the Medical Devices & Instruments industry.
Is Treace Medical Concepts' EV-to-EBIT too high?
Treace Medical Concepts' current EV-to-EBIT is -6.30. Based on the distribution chart, Treace Medical Concepts ranks #999999 out of 473 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Treace Medical Concepts has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Treace Medical Concepts' EV-to-EBIT compare to TLSI and SENS?
According to the Medical Devices & Instruments industry distribution chart, Treace Medical Concepts ranks #999999 out of 473 companies for EV-to-EBIT. This places Treace Medical Concepts in the lower half of its industry. The industry median EV-to-EBIT is 19.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.17, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Treace Medical Concepts and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Treace Medical Concepts's current EV-to-EBIT is -6.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Treace Medical Concepts stock overvalued right now?
Based on GuruFocus' analysis, Treace Medical Concepts (TMCI) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.35, compared to a current price of $4.79 — trading 24.6% below its estimated fair value. The current EV-to-EBIT is -6.30. Treace Medical Concepts' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Treace Medical Concepts (TMCI), the current EV-to-EBIT is -6.30 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Treace Medical Concepts (TMCI) Overvalued in 2026?
Based on GuruFocus' analysis, Treace Medical Concepts stock appears to be undervalued.
The current stock price of $4.79 is trading 24.6% below its estimated GF Value™ of $6.35.
GuruFocus considers Treace Medical Concepts to be Modestly Undervalued.
Key valuation signals for TMCI:
EV-to-EBIT: -6.30
GF Value™: $6.35 vs. price of $4.79 (24.6% below fair value)
No single metric tells the full story. See the TMCI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
68GF Score
Get the complete analysis for TMCI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMCI has been successfully added to your 
